Secondary Progressive Multiple Sclerosis Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG INDUSTRY

2.1 Summary about Secondary Progressive Multiple Sclerosis Drug Industry

2.2 Secondary Progressive Multiple Sclerosis Drug Market Trends

2.2.1 Secondary Progressive Multiple Sclerosis Drug Production & Consumption Trends

2.2.2 Secondary Progressive Multiple Sclerosis Drug Demand Structure Trends

2.3 Secondary Progressive Multiple Sclerosis Drug Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Inebilizumab 

4.2.2 GLX-1112 

4.2.3 DC-TAB 

4.2.4 Etomoxir 

4.2.5 IB-MS 

4.2.6 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospital 

4.3.2 Clinic 

4.3.3 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Inebilizumab 

5.2.2 GLX-1112 

5.2.3 DC-TAB 

5.2.4 Etomoxir 

5.2.5 IB-MS 

5.2.6 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospital 

5.3.2 Clinic 

5.3.3 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Inebilizumab 

6.2.2 GLX-1112 

6.2.3 DC-TAB 

6.2.4 Etomoxir 

6.2.5 IB-MS 

6.2.6 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospital 

6.3.2 Clinic 

6.3.3 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Inebilizumab 

7.2.2 GLX-1112 

7.2.3 DC-TAB 

7.2.4 Etomoxir 

7.2.5 IB-MS 

7.2.6 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospital 

7.3.2 Clinic 

7.3.3 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Inebilizumab 

8.2.2 GLX-1112 

8.2.3 DC-TAB 

8.2.4 Etomoxir 

8.2.5 IB-MS 

8.2.6 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospital 

8.3.2 Clinic 

8.3.3 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Inebilizumab 

9.2.2 GLX-1112 

9.2.3 DC-TAB 

9.2.4 Etomoxir 

9.2.5 IB-MS 

9.2.6 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospital 

9.3.2 Clinic 

9.3.3 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 AB Science SA 

10.1.2 Actelion Ltd 

10.1.3 Biogen, Inc. 

10.1.4 F. Hoffmann-La Roche Ltd. 

10.1.5 Genzyme Corporation 

10.1.6 Glialogix, Inc. 

10.1.7 Immune Response BioPharma, Inc. 

10.1.8 Innate Immunotherapeutics Ltd 

10.1.9 Kyorin Pharmaceutical Co., Ltd. 

10.1.10 Mallinckrodt Plc 

10.1.11 MedDay SA 

10.1.12 MedImmune, LLC 

10.1.13 Merck KGaA 

10.1.14 Meta-IQ ApS 

10.1.15 Novartis AG 

10.1.16 Opexa Therapeutics, Inc. 

10.1.17 Xenetic Biosciences (UK) Limited

10.2 Secondary Progressive Multiple Sclerosis Drug Sales Date of Major Players (2017-2020e)

10.2.1 AB Science SA 

10.2.2 Actelion Ltd 

10.2.3 Biogen, Inc. 

10.2.4 F. Hoffmann-La Roche Ltd. 

10.2.5 Genzyme Corporation 

10.2.6 Glialogix, Inc. 

10.2.7 Immune Response BioPharma, Inc. 

10.2.8 Innate Immunotherapeutics Ltd 

10.2.9 Kyorin Pharmaceutical Co., Ltd. 

10.2.10 Mallinckrodt Plc 

10.2.11 MedDay SA 

10.2.12 MedImmune, LLC 

10.2.13 Merck KGaA 

10.2.14 Meta-IQ ApS 

10.2.15 Novartis AG 

10.2.16 Opexa Therapeutics, Inc. 

10.2.17 Xenetic Biosciences (UK) Limited

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Secondary Progressive Multiple Sclerosis Drug Product Type Overview

Table Secondary Progressive Multiple Sclerosis Drug Product Type Market Share List

Table Secondary Progressive Multiple Sclerosis Drug Product Type of Major Players

Table Brief Introduction of AB Science SA 

Table Brief Introduction of Actelion Ltd 

Table Brief Introduction of Biogen, Inc. 

Table Brief Introduction of F. Hoffmann-La Roche Ltd. 

Table Brief Introduction of Genzyme Corporation 

Table Brief Introduction of Glialogix, Inc. 

Table Brief Introduction of Immune Response BioPharma, Inc. 

Table Brief Introduction of Innate Immunotherapeutics Ltd 

Table Brief Introduction of Kyorin Pharmaceutical Co., Ltd. 

Table Brief Introduction of Mallinckrodt Plc 

Table Brief Introduction of MedDay SA 

Table Brief Introduction of MedImmune, LLC 

Table Brief Introduction of Merck KGaA 

Table Brief Introduction of Meta-IQ ApS 

Table Brief Introduction of Novartis AG 

Table Brief Introduction of Opexa Therapeutics, Inc. 

Table Brief Introduction of Xenetic Biosciences (UK) Limited

Table Products & Services of AB Science SA 

Table Products & Services of Actelion Ltd 

Table Products & Services of Biogen, Inc. 

Table Products & Services of F. Hoffmann-La Roche Ltd. 

Table Products & Services of Genzyme Corporation 

Table Products & Services of Glialogix, Inc. 

Table Products & Services of Immune Response BioPharma, Inc. 

Table Products & Services of Innate Immunotherapeutics Ltd 

Table Products & Services of Kyorin Pharmaceutical Co., Ltd. 

Table Products & Services of Mallinckrodt Plc 

Table Products & Services of MedDay SA 

Table Products & Services of MedImmune, LLC 

Table Products & Services of Merck KGaA 

Table Products & Services of Meta-IQ ApS 

Table Products & Services of Novartis AG 

Table Products & Services of Opexa Therapeutics, Inc. 

Table Products & Services of Xenetic Biosciences (UK) Limited

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Region 2021f-2026f

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Demand 2021f-2026f